Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference
Tricida, Inc. (Nasdaq: TCDA) will present at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tricida, Inc. (Nasdaq: TCDA) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 10:30 am PT. Gerrit Klaerner, Ph.D., President and CEO, will discuss the company's overview, business updates, and key initiatives. The presentation will be available via a live webcast on the Tricida website, with an archive accessible for 30 days post-event.
Tricida focuses on developing veverimer, a drug aimed at slowing chronic kidney disease (CKD) progression. This condition affects approximately three million patients in the U.S., with no current FDA-approved therapies targeting metabolic acidosis in CKD.
Details
News Market Reaction – TCDA
The recorded move for TCDA in the trading session of this news was +4.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 am PT / 1:30 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives.
A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 30 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit www.Tricida.com.
Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.